Vancouver-based AI drug discovery company AbCellera Biologics entered a strategic collaboration with British biotechnology company RQ Bio to identify clinical candidates for three infectious disease targets chosen by RQ Bio, including influenza and cytomegalovirus (CMV).
The partnership combines RQ Bio’s experience in viral and infectious diseases with AbCellera’s discovery engine, enabling faster development of new medicines for high-risk patients.
Under the terms of the agreement, AbCellera will receive payments for research and could receive additional payments upon completion of clinical and regulatory milestones, as well as a percentage of product sales revenue. RQ Bio is authorized to advance and market therapeutic antibodies generated from the partnership.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.